Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
The Medical Journal of Malaysia ; : 396-399, 2020.
Article in English | WPRIM | ID: wpr-829837

ABSTRACT

@#Cirrhotic cardiomyopathy is a recognised complication of liver cirrhosis and predicts poor outcomes. Detection of diastolic dysfunction, an early indicator of left ventricular dysfunction can help identify those patients at risk of disease progression. In our study we showed that there was a high prevalence of diastolic dysfunction amongst patients with liver cirrhosis at our outpatient clinic, with the majority being Child-Pugh A/low MELD score. Multiple regression analysis indicated that age and sodium levels were significantly associated with the presence of diastolic dysfunction. This further reinforces the importance of dietary sodium restriction amongst patients with liver cirrhosis.

2.
Intestinal Research ; : 285-310, 2019.
Article in English | WPRIM | ID: wpr-764161

ABSTRACT

The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in the conjunction with conventional treatments for ulcerative colitis (UC) and Crohn's disease (CD) in Asia. These statements also address how pharmacogenetics influence the treatments of UC and CD and provide guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of IBD workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing and future revisions are likely as new data continue to emerge.


Subject(s)
Humans , Adalimumab , Asia , Asian People , Biological Factors , Biosimilar Pharmaceuticals , Colitis , Colitis, Ulcerative , Consensus , Cooperative Behavior , Crohn Disease , Gastroenterology , Hepatitis B , Immunologic Factors , Inflammatory Bowel Diseases , Infliximab , Pharmacogenetics , Philippines , Practice Guidelines as Topic , Tuberculosis , Ulcer
SELECTION OF CITATIONS
SEARCH DETAIL